0001788542-23-000006.txt : 20230721
0001788542-23-000006.hdr.sgml : 20230721
20230721174651
ACCESSION NUMBER: 0001788542-23-000006
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230719
FILED AS OF DATE: 20230721
DATE AS OF CHANGE: 20230721
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mottiwala Aziz
CENTRAL INDEX KEY: 0001788542
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39614
FILM NUMBER: 231103403
MAIL ADDRESS:
STREET 1: 233 WILSHIRE BOULEVARD
STREET 2: SUITE 280
CITY: SANTA MONICA
STATE: CA
ZIP: 90401
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Tarsus Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001819790
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 814717861
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 15440 LAGUNA CANYON ROAD
CITY: IRVINE
STATE: CA
ZIP: 92618
BUSINESS PHONE: (949) 409-9820
MAIL ADDRESS:
STREET 1: 15440 LAGUNA CANYON ROAD
CITY: IRVINE
STATE: CA
ZIP: 92618
4
1
wk-form4_1689976000.xml
FORM 4
X0508
4
2023-07-19
0
0001819790
Tarsus Pharmaceuticals, Inc.
TARS
0001788542
Mottiwala Aziz
C/O TARSUS PHARMACEUTICALS, INC.
15440 LAGUNA CANYON ROAD, SUITE 160
IRVINE
CA
92618
0
1
0
0
Chief Commercial Officer
1
Common Stock
2023-07-19
4
S
0
2400
20.05
D
45806
D
The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 26, 2022.
The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $20.00 to $20.10. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Includes 120 shares acquired under the Issuer's employee stock purchase plan on June 30, 2023.
/s/ Jeffrey Farrow, Attorney-in-Fact
2023-07-21